Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00262314 · ClinicalTrials.gov registry record

Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients

A clinical trial of Multiple Sclerosis, sponsored by EMD Serono.

Completed
Registry status
509
Enrollment target
1
Study location

NCT00262314 is a study of Multiple Sclerosis that has completed, run by EMD Serono. The registered enrollment target is 509 participants, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (13% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00262314, a study of Multiple Sclerosis, has completed, sponsored by EMD Serono.

COMPLETED
Registry status
509 participants
Enrollment target
1
Study location

Study Summary

The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.

Conditions Studied

Study Locations (1)

Kentucky

  • Registrat Inc - Lexington

Trial Details

FieldValue
Enrollment Target 509 participants
Start Date 2000-10
Est. Completion 2008-09

Sponsor

EMD Serono

71 total trials

What the Registry Record Tells You About NCT00262314

The ClinicalTrials.gov registry entry for NCT00262314 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 509 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (13% lower). The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.

NCT00262314 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.

Frequently Asked Questions

What is clinical trial NCT00262314 about?

NCT00262314 is a clinical study titled "Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients". The overall objective of this study is to collect data relevant to the tolerability of Novantrone® therapy in patients with multiple sclerosis (MS) using dosing and monitoring recommendations specified in the package insert.

What is the current status of trial NCT00262314?

This trial is currently completed. The enrollment target is 509 participants. The study started on 2000-10. Estimated completion is 2008-09.

What conditions does trial NCT00262314 study?

This clinical trial studies the following conditions: Multiple Sclerosis.

Who is sponsoring clinical trial NCT00262314?

This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00262314 being conducted?

This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.